Accredited Continuing Education

The deadline for claiming CME for this event was June 30, 2023.

Please contact [email protected] if you require assistance.

Accreditation Statement

The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Interventional Cardiology Program Credit Designation

SCAI designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Congenital Heart Disease Program Credit Designation

SCAI designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABP MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.75 medical knowledge MOC points in the American Board of Pediatric’s (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Nurses

Approved for Registered Nurses by the Alliance of Cardiovascular Professionals’ CaPCE accreditation program for up to 16.75 contact hours of accredited education. Provider approved by the California Board of Registered Nursing, BRN Provider #15311.

Radiologic Technologists

Approved by the AVIR for 16.75 Category A+ CEs.

Successful Completion

Check into the conference onsite and pick up your badge. This creates an attendance record. Participate in the program. Then, complete the post-activity evaluation to claim credit.

Acknowledgment of Commercial Support

Scientific Sessions is supported by unrestricted educational grants from Abbott, Abiomed, Boston Scientific, Cordis, Medtronic, Merit Medical, Edwards Lifesciences, Shockwave Medical, Siemens Healthineer, Terumo Medical, and Teleflex.

SCAI-Sponsored Satellite Symposia Programming

In addition to the Scientific Sessions program described above, SCAI offers CME satellite symposia opportunities. These symposia represent a possible additional 14.75 AMA PRA Category 1 Credits^TM. CE information for the satellite symposia can be found in the conference program.

Disclosures

Individuals in control of content disclosed the following relevant relationships with ineligible companies during the content development process for this activity.

Program Committee/Planners

Program Chairs

J. Dawn Abbott: Consulting with Abbott, Medtronic, Philips, Recor - Consulting. Grants from Boston Scientific Corp., and Microport.
Binita Shah: Advisory board with Philips. Consulting with Terumo Medical
Sahil Parikh: Abbott Vascular, Shockwave Medical, TriReme Medical, Surmodics, and Silk Road Medical; has received consulting fees from Terumo and Abiomed; and has served on the Advisory Boards of Abbott, Medtronic, and Boston Scientific

Case Exchange Track

Mirvat Alasnag and Ramesh Daggubati: No financial relationships with ineligible companies.

Congenital Heart Disease Program

David T. Balzer: PI and proctor with Edwards Lifesciences and Medtronic.
Zahid Amin: Consultig with Edwards Lifesciences. Speaker with Abbott.
Howaida El-Said: No financial relationships with ineligible companies.

Coronary Track

Jay Bagai: No financial relationships with ineligible companies.
Luiz F. Ybarra: Advisory board and speaker with Abbott.
Rajan A. Patel: Advisory board and speaker with Abiomed. Speaker with Liva Nova.
Evan Shlofmitz: Speaker with Amgen, Janssen Pharmaceuticals, Novo Nordisk. Consulting with Abbott, ACIST Medical, Boston Scientific, Chiesi, Philips, Shockwave Medical, Terumo, Xenter.

Interventional Leadership Track

Lyndon Box, Sohah N. Iqbal, Guarav Tyagi: No financial relationships with ineligible companies.
Arnold H. Seto: Consulting and PI with Frond Medical. Speaker with General Electric, Terumo, and Janssen.

Peripheral Track

Beau M. Hawkins: PI with Boston Scientific Corp., Behring and Hemostemix.
Sasanka Jayasuriya: No financial relationships with ineligible companies.
J. Antonio Gutierrez: Advisory board with Amgen and Janssen. Consulting with Medicure.
Jon C. George: Consulting with Avinger and Medtronic Avinger.

Structural Track

George S. Hanzel: Consulting with Medtronic.
Triston B.B.J. Smith: Consulting with Edwards Lifesciences. Speaker with Zoll.
Ranya Sweis: Speaker with Abiomed.
Azeem Latib: No financial relationships with ineligible companies.

Staff

Robert Bartel and Rachel Pham have no financial relationships with ineligible companies.

Faculty disclosures can be found in the Conference App under the Faculty Listing.

Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 

The SCAI 2024 Scientific Sessions were developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships

All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement

SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Questions?

If you have any questions or concerns about your assignments, please email:

[email protected]

SCAI 2024 Scientific Sessions